Start Your Search
Poster Display session (Friday) (ID 65)
- Event: ELCC 2018
- Type: Poster Display session
- Presentations: 1
- Coordinates: 4/13/2018, 12:30 - 13:00, Hall 1
164P - Feasibility of liquid biopsy using plasma and platelets for detection of ALK rearrangements in non-small cell lung cancer (ID 297)
12:30 - 13:00 | Author(s): Y. Kim
The aim of this study is to investigate the feasibility of liquid biopsy using plasma and platelets for detection of ALK rearrangement.
FISH was performed in 664 patients between January 2015 and May 2017. We retrospectively analyzed the FFPE tissue and blood sample to detect ALK rearrangement using multiplex RT-PCR from 30 advanced NSCLC patients who had available tissue specimen. Total RNA were extracted from FFPE cell blocks, plasma and platelets, respectively. EML4-ALK fusion RNA was detected using PANAqPCR[TM] EML4-ALK fusion gene detection kit.
28 patients were FISH positive and 2 were negative. In a validation data compared with FISH, RT-PCR using FFPE tissue demonstrated 57.1% sensitivity and 69.2% accuracy. Liquid biopsy (plasma or platelets-positive) had higher sensitivity (96.4%) and accuracy (93.3%). Among the specimen of liquid biopsy, platelets showed slightly higher sensitivity and accuracy than plasma (82.1 and 83.3% vs 78.6 and 76.7%). Compared with FFPE tissue using RT-PCR, liquid biopsy showed 100% sensitivity, 20.0% specificity and 69.2% accuracy. Median proportion of positive cells in FISH was higher in subgroups of liquid biopsy with positive result (Plasma, 30.0 vs 15.0%, p = 0.062; Platelets 30.0 vs 20.0%, p = 0.104). In 18 patients with crizotinib treatment, platelets-positive subgroup showed a tendency of longer duration of treatment (7.2 vs 1.5 months, p = 0.071) and higher response rate (57.1 vs 0.0%, p = 0.092). However, platelets-positive subgroup showed significantly higher disease control rate than platelets-negative subgroup when they were treated with crizotinib (85.7 vs 25.0%, p = 0.044).
Plasma and platelets are valuable sources for liquid biopsy using RT-PCR technique in detection of ALK rearrangement, and could play a supplementary role in diagnosis of ALK-positive NSCLC. Furthermore, platelets may be useful for predicting the treatment outcome of crizotinib.
Clinical trial identification:
Legal entity responsible for the study:
Legal entity responsible for the study
Has not received any funding
All authors have declared no conflicts of interest.
Only Active Members that have purchased this event or have registered via an access code will be able to view this content. To view this presentation, please login or select "Add to Cart" and proceed to checkout.